| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 149 | 2024 | 7055 | 13.000 |
Why?
|
| Transplantation Conditioning | 83 | 2024 | 2374 | 8.510 |
Why?
|
| Graft vs Host Disease | 68 | 2024 | 2811 | 7.300 |
Why?
|
| HLA Antigens | 21 | 2024 | 593 | 6.260 |
Why?
|
| Transplantation, Haploidentical | 17 | 2024 | 159 | 5.350 |
Why?
|
| Hematologic Neoplasms | 28 | 2024 | 1956 | 4.280 |
Why?
|
| Transplantation, Homologous | 62 | 2024 | 3048 | 4.060 |
Why?
|
| Cyclophosphamide | 34 | 2024 | 3246 | 4.030 |
Why?
|
| Leukemia, Myeloid, Acute | 50 | 2024 | 7274 | 3.960 |
Why?
|
| Unrelated Donors | 15 | 2023 | 321 | 3.540 |
Why?
|
| Histocompatibility Testing | 18 | 2024 | 488 | 3.440 |
Why?
|
| Stem Cell Transplantation | 20 | 2021 | 1420 | 3.010 |
Why?
|
| Melphalan | 16 | 2022 | 879 | 2.690 |
Why?
|
| Killer Cells, Natural | 10 | 2024 | 967 | 2.610 |
Why?
|
| Tissue Donors | 14 | 2024 | 819 | 2.380 |
Why?
|
| Immunosuppressive Agents | 13 | 2021 | 1436 | 1.830 |
Why?
|
| Myelodysplastic Syndromes | 20 | 2022 | 3155 | 1.810 |
Why?
|
| Isoantibodies | 4 | 2024 | 121 | 1.780 |
Why?
|
| Allografts | 27 | 2024 | 687 | 1.760 |
Why?
|
| Graft Survival | 10 | 2020 | 1076 | 1.680 |
Why?
|
| Myeloablative Agonists | 11 | 2021 | 388 | 1.620 |
Why?
|
| Graft Rejection | 7 | 2024 | 844 | 1.610 |
Why?
|
| Mycophenolic Acid | 5 | 2019 | 153 | 1.530 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2019 | 382 | 1.470 |
Why?
|
| T-Lymphocytes | 15 | 2024 | 3946 | 1.450 |
Why?
|
| Haplotypes | 11 | 2024 | 908 | 1.440 |
Why?
|
| Primary Myelofibrosis | 9 | 2021 | 913 | 1.440 |
Why?
|
| Bone Marrow Transplantation | 9 | 2024 | 1754 | 1.370 |
Why?
|
| Busulfan | 17 | 2022 | 794 | 1.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2023 | 2903 | 1.370 |
Why?
|
| Humans | 223 | 2024 | 270709 | 1.350 |
Why?
|
| Middle Aged | 133 | 2024 | 90517 | 1.310 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2019 | 372 | 1.310 |
Why?
|
| Tacrolimus | 5 | 2019 | 347 | 1.290 |
Why?
|
| Recurrence | 31 | 2024 | 4878 | 1.260 |
Why?
|
| Adult | 123 | 2024 | 82042 | 1.220 |
Why?
|
| Vidarabine | 19 | 2022 | 1384 | 1.200 |
Why?
|
| Multiple Myeloma | 13 | 2023 | 2336 | 1.140 |
Why?
|
| Neoplasm, Residual | 8 | 2022 | 1761 | 1.120 |
Why?
|
| Young Adult | 55 | 2024 | 22241 | 1.070 |
Why?
|
| Aged | 98 | 2024 | 73601 | 1.070 |
Why?
|
| Donor Selection | 6 | 2022 | 110 | 0.970 |
Why?
|
| Lymphoma | 8 | 2019 | 1516 | 0.970 |
Why?
|
| Female | 127 | 2024 | 148873 | 0.960 |
Why?
|
| Male | 120 | 2024 | 128479 | 0.960 |
Why?
|
| Survival Rate | 40 | 2021 | 12528 | 0.940 |
Why?
|
| Disease-Free Survival | 33 | 2021 | 10268 | 0.930 |
Why?
|
| Immune Reconstitution | 1 | 2024 | 25 | 0.920 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 513 | 0.910 |
Why?
|
| Adolescent | 53 | 2024 | 32691 | 0.870 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2020 | 107 | 0.840 |
Why?
|
| Refrigeration | 1 | 2022 | 15 | 0.820 |
Why?
|
| Hodgkin Disease | 5 | 2020 | 1485 | 0.820 |
Why?
|
| Herpesvirus 6, Human | 1 | 2023 | 81 | 0.810 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 10409 | 0.810 |
Why?
|
| Retrospective Studies | 63 | 2024 | 39968 | 0.810 |
Why?
|
| Antibodies, Bispecific | 2 | 2023 | 282 | 0.800 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2022 | 2636 | 0.790 |
Why?
|
| Lymphocyte Depletion | 5 | 2018 | 316 | 0.790 |
Why?
|
| Histocompatibility | 5 | 2022 | 183 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2024 | 16750 | 0.750 |
Why?
|
| Remission Induction | 17 | 2022 | 3658 | 0.740 |
Why?
|
| Autoimmune Diseases | 2 | 2023 | 435 | 0.720 |
Why?
|
| Treatment Outcome | 52 | 2024 | 33847 | 0.700 |
Why?
|
| Models, Biological | 3 | 2020 | 3187 | 0.690 |
Why?
|
| Transplantation, Autologous | 13 | 2023 | 2073 | 0.670 |
Why?
|
| Leukemia | 6 | 2021 | 1719 | 0.670 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2020 | 1068 | 0.650 |
Why?
|
| Psoriasis | 1 | 2019 | 144 | 0.600 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 87 | 0.570 |
Why?
|
| Survival Analysis | 21 | 2021 | 9278 | 0.560 |
Why?
|
| Rituximab | 8 | 2021 | 1594 | 0.550 |
Why?
|
| Cyclosporine | 1 | 2017 | 293 | 0.530 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 204 | 0.510 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2018 | 838 | 0.510 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 232 | 0.510 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2024 | 1860 | 0.510 |
Why?
|
| Prognosis | 26 | 2022 | 22528 | 0.510 |
Why?
|
| Bone Marrow | 7 | 2021 | 2440 | 0.500 |
Why?
|
| Interleukins | 1 | 2017 | 339 | 0.490 |
Why?
|
| Drug Discovery | 1 | 2017 | 329 | 0.470 |
Why?
|
| Collagen | 1 | 2017 | 724 | 0.460 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1388 | 0.440 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 750 | 0.440 |
Why?
|
| Antigens, CD19 | 3 | 2024 | 585 | 0.420 |
Why?
|
| Bortezomib | 4 | 2023 | 551 | 0.420 |
Why?
|
| Akinetic Mutism | 1 | 2012 | 3 | 0.420 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 15274 | 0.420 |
Why?
|
| Transforming Growth Factor beta | 3 | 2020 | 1105 | 0.410 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 605 | 0.410 |
Why?
|
| Haploidy | 4 | 2014 | 43 | 0.400 |
Why?
|
| Fibroblasts | 2 | 2020 | 1647 | 0.390 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4392 | 0.390 |
Why?
|
| Chimerism | 3 | 2022 | 65 | 0.390 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 704 | 0.380 |
Why?
|
| Cytomegalovirus Infections | 3 | 2021 | 491 | 0.370 |
Why?
|
| HLA-A Antigens | 1 | 2011 | 105 | 0.370 |
Why?
|
| Cytarabine | 6 | 2024 | 2015 | 0.370 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2011 | 58 | 0.360 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 129 | 0.360 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 135 | 0.350 |
Why?
|
| Thrombopoietin | 2 | 2007 | 102 | 0.350 |
Why?
|
| Leukemia, Myeloid | 2 | 2016 | 993 | 0.350 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 14639 | 0.340 |
Why?
|
| BK Virus | 1 | 2011 | 126 | 0.340 |
Why?
|
| Adenine Nucleotides | 4 | 2016 | 364 | 0.340 |
Why?
|
| Polyomavirus Infections | 1 | 2011 | 147 | 0.340 |
Why?
|
| Antilymphocyte Serum | 4 | 2022 | 236 | 0.340 |
Why?
|
| Ureteral Obstruction | 1 | 2011 | 141 | 0.340 |
Why?
|
| Megakaryocytes | 2 | 2007 | 128 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2017 | 7233 | 0.330 |
Why?
|
| Prospective Studies | 13 | 2024 | 13407 | 0.330 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 1837 | 0.330 |
Why?
|
| Whole-Body Irradiation | 3 | 2019 | 323 | 0.330 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 871 | 0.320 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2024 | 750 | 0.320 |
Why?
|
| Arabinonucleosides | 4 | 2016 | 470 | 0.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2022 | 1740 | 0.320 |
Why?
|
| Consensus | 3 | 2024 | 1113 | 0.310 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2015 | 770 | 0.310 |
Why?
|
| Myeloproliferative Disorders | 4 | 2022 | 882 | 0.310 |
Why?
|
| Antibodies | 1 | 2011 | 801 | 0.310 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 39 | 0.300 |
Why?
|
| ABO Blood-Group System | 3 | 2016 | 125 | 0.300 |
Why?
|
| Anemia, Hemolytic | 1 | 2008 | 53 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 4965 | 0.300 |
Why?
|
| Thrombopoiesis | 1 | 2007 | 23 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2017 | 271 | 0.290 |
Why?
|
| Splenomegaly | 1 | 2008 | 172 | 0.290 |
Why?
|
| Lymphocyte Transfusion | 4 | 2017 | 174 | 0.290 |
Why?
|
| Lymphocytes | 2 | 2019 | 1273 | 0.280 |
Why?
|
| Risk Factors | 14 | 2020 | 17850 | 0.280 |
Why?
|
| Incidence | 9 | 2021 | 5814 | 0.280 |
Why?
|
| Cytomegalovirus | 2 | 2021 | 494 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 3656 | 0.280 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2017 | 2488 | 0.280 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2017 | 1362 | 0.280 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 15 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2021 | 6255 | 0.270 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 718 | 0.270 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 5093 | 0.270 |
Why?
|
| Cerebral Veins | 1 | 2006 | 29 | 0.260 |
Why?
|
| Jehovah's Witnesses | 1 | 2006 | 23 | 0.260 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2006 | 75 | 0.260 |
Why?
|
| Janus Kinase 2 | 5 | 2017 | 755 | 0.260 |
Why?
|
| Gallbladder Neoplasms | 1 | 2008 | 244 | 0.260 |
Why?
|
| Blood Preservation | 1 | 2006 | 60 | 0.260 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 350 | 0.260 |
Why?
|
| Acute Disease | 8 | 2022 | 2491 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 128 | 0.250 |
Why?
|
| Romania | 7 | 2016 | 21 | 0.250 |
Why?
|
| Age Factors | 7 | 2020 | 5436 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 213 | 0.240 |
Why?
|
| Combined Modality Therapy | 12 | 2020 | 9054 | 0.240 |
Why?
|
| Erythropoietin | 1 | 2006 | 224 | 0.240 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 557 | 0.240 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2016 | 50 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2008 | 669 | 0.230 |
Why?
|
| Feasibility Studies | 6 | 2020 | 2360 | 0.230 |
Why?
|
| Neutrophils | 3 | 2019 | 855 | 0.230 |
Why?
|
| Heterocyclic Compounds | 2 | 2015 | 117 | 0.220 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Foscarnet | 1 | 2023 | 19 | 0.220 |
Why?
|
| Chromosome Aberrations | 3 | 2020 | 2035 | 0.220 |
Why?
|
| Adenoma | 1 | 2008 | 738 | 0.210 |
Why?
|
| Child | 16 | 2024 | 30563 | 0.210 |
Why?
|
| Blast Crisis | 2 | 2021 | 588 | 0.210 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2023 | 65 | 0.210 |
Why?
|
| Salvage Therapy | 4 | 2024 | 2124 | 0.210 |
Why?
|
| Polyvinyl Chloride | 1 | 2022 | 9 | 0.210 |
Why?
|
| Drug Packaging | 1 | 2022 | 13 | 0.210 |
Why?
|
| beta-Cyclodextrins | 1 | 2022 | 19 | 0.210 |
Why?
|
| Factor V Deficiency | 1 | 2022 | 2 | 0.210 |
Why?
|
| Propylene Glycols | 1 | 2022 | 38 | 0.210 |
Why?
|
| Drug Stability | 1 | 2022 | 105 | 0.200 |
Why?
|
| Drug Storage | 1 | 2022 | 29 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 380 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 1 | 2006 | 364 | 0.200 |
Why?
|
| Sodium Chloride | 1 | 2022 | 159 | 0.200 |
Why?
|
| Medicine | 1 | 2023 | 134 | 0.200 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 1420 | 0.200 |
Why?
|
| von Willebrand Diseases | 1 | 2022 | 55 | 0.190 |
Why?
|
| Cause of Death | 4 | 2018 | 780 | 0.190 |
Why?
|
| Transplantation Immunology | 3 | 2019 | 107 | 0.190 |
Why?
|
| Thalidomide | 2 | 2017 | 597 | 0.190 |
Why?
|
| Aging | 1 | 2009 | 1531 | 0.190 |
Why?
|
| Community Health Planning | 1 | 2020 | 23 | 0.180 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 182 | 0.180 |
Why?
|
| Epitopes | 1 | 2023 | 699 | 0.180 |
Why?
|
| Thiotepa | 2 | 2012 | 132 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 878 | 0.180 |
Why?
|
| Temperature | 1 | 2022 | 534 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1580 | 0.180 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2022 | 590 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2023 | 748 | 0.180 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 2 | 2022 | 107 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 2343 | 0.180 |
Why?
|
| Photopheresis | 1 | 2021 | 79 | 0.180 |
Why?
|
| Seizures | 1 | 2006 | 996 | 0.170 |
Why?
|
| Living Donors | 3 | 2021 | 170 | 0.170 |
Why?
|
| Virus Activation | 2 | 2019 | 241 | 0.170 |
Why?
|
| Cytokines | 2 | 2016 | 2803 | 0.170 |
Why?
|
| Core Binding Factors | 1 | 2020 | 112 | 0.160 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 20 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 4470 | 0.160 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2016 | 123 | 0.160 |
Why?
|
| Blood Platelets | 3 | 2015 | 675 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 286 | 0.160 |
Why?
|
| Antigens, CD34 | 3 | 2013 | 639 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 5053 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2020 | 135 | 0.160 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 46 | 0.160 |
Why?
|
| Child, Preschool | 9 | 2024 | 17076 | 0.160 |
Why?
|
| Preoperative Period | 2 | 2017 | 348 | 0.160 |
Why?
|
| Yttrium Radioisotopes | 2 | 2018 | 211 | 0.160 |
Why?
|
| Neoplasms | 5 | 2018 | 15951 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 551 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 89 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 1550 | 0.150 |
Why?
|
| Graft vs Tumor Effect | 1 | 2017 | 143 | 0.150 |
Why?
|
| Karyotype | 1 | 2018 | 237 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2021 | 375 | 0.150 |
Why?
|
| Acrylates | 1 | 2017 | 33 | 0.140 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 574 | 0.140 |
Why?
|
| Alleles | 2 | 2016 | 2597 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 405 | 0.140 |
Why?
|
| K562 Cells | 1 | 2017 | 344 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 3840 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 726 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 271 | 0.140 |
Why?
|
| Body Fluids | 1 | 2017 | 121 | 0.140 |
Why?
|
| Single-Chain Antibodies | 1 | 2017 | 61 | 0.140 |
Why?
|
| Cohort Studies | 7 | 2022 | 9451 | 0.130 |
Why?
|
| San Francisco | 1 | 2016 | 23 | 0.130 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 117 | 0.130 |
Why?
|
| Transplantation, Isogeneic | 1 | 2016 | 67 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6232 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 12974 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 1136 | 0.130 |
Why?
|
| Karyotyping | 1 | 2018 | 1064 | 0.130 |
Why?
|
| Premedication | 1 | 2016 | 132 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 1195 | 0.130 |
Why?
|
| Risk | 2 | 2017 | 1929 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2018 | 300 | 0.130 |
Why?
|
| Steroids | 3 | 2023 | 372 | 0.130 |
Why?
|
| Edema | 1 | 2017 | 264 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 686 | 0.130 |
Why?
|
| Rhodamines | 1 | 2015 | 47 | 0.130 |
Why?
|
| Consolidation Chemotherapy | 1 | 2016 | 153 | 0.130 |
Why?
|
| Morpholines | 1 | 2017 | 296 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Blood Donors | 2 | 2019 | 173 | 0.130 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2015 | 63 | 0.120 |
Why?
|
| Hematology | 1 | 2016 | 98 | 0.120 |
Why?
|
| DNA Transposable Elements | 1 | 2016 | 240 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| Photosensitizing Agents | 1 | 2015 | 82 | 0.120 |
Why?
|
| Cells, Cultured | 2 | 2017 | 5658 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 31113 | 0.120 |
Why?
|
| Cell Engineering | 1 | 2014 | 35 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 462 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 74 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2016 | 311 | 0.110 |
Why?
|
| Fibrosis | 1 | 2017 | 715 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2019 | 1525 | 0.110 |
Why?
|
| Kinetics | 1 | 2017 | 2206 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2018 | 2259 | 0.110 |
Why?
|
| Polycythemia Vera | 2 | 2007 | 269 | 0.110 |
Why?
|
| Recombinant Proteins | 3 | 2009 | 2986 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2020 | 1185 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 3429 | 0.110 |
Why?
|
| Mutation | 4 | 2018 | 15922 | 0.110 |
Why?
|
| Lymphocyte Count | 2 | 2015 | 485 | 0.110 |
Why?
|
| Chronic Disease | 4 | 2021 | 1824 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 1337 | 0.110 |
Why?
|
| Proteome | 1 | 2017 | 571 | 0.110 |
Why?
|
| Immunity, Innate | 2 | 2021 | 697 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2017 | 316 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 1581 | 0.110 |
Why?
|
| Nitrophenols | 1 | 2013 | 95 | 0.110 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 58 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 930 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 629 | 0.100 |
Why?
|
| Medicare | 1 | 2018 | 924 | 0.100 |
Why?
|
| Transplantation Chimera | 3 | 2021 | 174 | 0.100 |
Why?
|
| Nuclear Family | 1 | 2012 | 68 | 0.100 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4893 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2019 | 901 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 306 | 0.100 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 188 | 0.100 |
Why?
|
| Alemtuzumab | 1 | 2012 | 213 | 0.100 |
Why?
|
| Fetal Blood | 1 | 2015 | 494 | 0.100 |
Why?
|
| Platelet Transfusion | 2 | 2015 | 166 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2018 | 2855 | 0.100 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2011 | 35 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 1944 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 758 | 0.100 |
Why?
|
| Indazoles | 1 | 2013 | 310 | 0.100 |
Why?
|
| Disease Progression | 2 | 2020 | 6880 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 7920 | 0.100 |
Why?
|
| Retreatment | 3 | 2018 | 449 | 0.100 |
Why?
|
| Immunotherapy | 5 | 2023 | 3561 | 0.090 |
Why?
|
| Polyethylene Glycols | 2 | 2023 | 652 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2017 | 1429 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 676 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2011 | 332 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 206 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2019 | 6765 | 0.090 |
Why?
|
| Animals | 7 | 2022 | 61350 | 0.090 |
Why?
|
| Hepatectomy | 4 | 2006 | 1013 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2012 | 355 | 0.090 |
Why?
|
| Etoposide | 3 | 2023 | 908 | 0.090 |
Why?
|
| Transplantation | 1 | 2010 | 55 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3463 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2017 | 1243 | 0.090 |
Why?
|
| Pancreatectomy | 2 | 2005 | 690 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 352 | 0.090 |
Why?
|
| Liver Neoplasms | 5 | 2006 | 4842 | 0.090 |
Why?
|
| Isoantigens | 1 | 2009 | 66 | 0.090 |
Why?
|
| Autografts | 2 | 2022 | 180 | 0.080 |
Why?
|
| Filgrastim | 1 | 2009 | 194 | 0.080 |
Why?
|
| Pyrazines | 1 | 2012 | 511 | 0.080 |
Why?
|
| Cell Line | 1 | 2017 | 5313 | 0.080 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2017 | 460 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 799 | 0.080 |
Why?
|
| Proteasome Inhibitors | 2 | 2023 | 235 | 0.080 |
Why?
|
| Texas | 2 | 2018 | 6445 | 0.080 |
Why?
|
| Apoptosis | 3 | 2017 | 7757 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 729 | 0.080 |
Why?
|
| Siblings | 2 | 2021 | 319 | 0.080 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2008 | 43 | 0.080 |
Why?
|
| Carmustine | 2 | 2019 | 225 | 0.080 |
Why?
|
| Genes, abl | 1 | 2008 | 119 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 685 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4964 | 0.080 |
Why?
|
| Contraindications | 1 | 2008 | 153 | 0.070 |
Why?
|
| United States | 6 | 2022 | 15817 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1347 | 0.070 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2008 | 75 | 0.070 |
Why?
|
| Age Distribution | 1 | 2009 | 726 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2005 | 2192 | 0.070 |
Why?
|
| Integrin beta3 | 1 | 2007 | 45 | 0.070 |
Why?
|
| Platelet Count | 1 | 2008 | 488 | 0.070 |
Why?
|
| bcl-X Protein | 1 | 2007 | 200 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7917 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2012 | 636 | 0.070 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 254 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2922 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2022 | 1061 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2008 | 726 | 0.070 |
Why?
|
| Obesity | 1 | 2018 | 2888 | 0.070 |
Why?
|
| Liver Transplantation | 3 | 2005 | 1188 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 4103 | 0.070 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 574 | 0.060 |
Why?
|
| Monosomy | 2 | 2017 | 98 | 0.060 |
Why?
|
| Comorbidity | 3 | 2018 | 2393 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2007 | 571 | 0.060 |
Why?
|
| Family | 1 | 2009 | 782 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2005 | 113 | 0.060 |
Why?
|
| Syndrome | 1 | 2008 | 1408 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2008 | 579 | 0.060 |
Why?
|
| Propensity Score | 2 | 2019 | 772 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4315 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2009 | 1420 | 0.060 |
Why?
|
| Benzylamines | 2 | 2015 | 98 | 0.060 |
Why?
|
| Mice | 4 | 2022 | 35420 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2013 | 1943 | 0.060 |
Why?
|
| Catheter Ablation | 2 | 2006 | 574 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2006 | 600 | 0.050 |
Why?
|
| Liver Abscess | 1 | 2003 | 37 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2023 | 134 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 105 | 0.050 |
Why?
|
| Asparaginase | 1 | 2023 | 196 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3345 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 7323 | 0.050 |
Why?
|
| HLA-DP beta-Chains | 1 | 2022 | 16 | 0.050 |
Why?
|
| Receptors, KIR | 1 | 2022 | 64 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2006 | 958 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 3054 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 214 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2007 | 600 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2018 | 984 | 0.050 |
Why?
|
| Leukocytosis | 1 | 2022 | 122 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 1998 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 14885 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2454 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 225 | 0.050 |
Why?
|
| Marital Status | 1 | 2020 | 89 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2023 | 573 | 0.040 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2020 | 37 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2022 | 245 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 178 | 0.040 |
Why?
|
| Thymectomy | 1 | 2000 | 80 | 0.040 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 50 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2020 | 271 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 119 | 0.040 |
Why?
|
| Hemangioma | 1 | 2001 | 160 | 0.040 |
Why?
|
| Methotrexate | 1 | 2023 | 1025 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2020 | 296 | 0.040 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2000 | 152 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2022 | 698 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 66 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 212 | 0.040 |
Why?
|
| Calcineurin Inhibitors | 1 | 2019 | 68 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 325 | 0.040 |
Why?
|
| Vincristine | 1 | 2023 | 1583 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3929 | 0.040 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2000 | 211 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2020 | 214 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 809 | 0.040 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2018 | 8 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 280 | 0.040 |
Why?
|
| Hemoglobinopathies | 1 | 2018 | 25 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 174 | 0.040 |
Why?
|
| Liver Cirrhosis | 2 | 2005 | 1048 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 724 | 0.040 |
Why?
|
| California | 1 | 2018 | 209 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1456 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 4808 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2017 | 88 | 0.040 |
Why?
|
| Lung | 1 | 2008 | 3287 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 572 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 3 | 2005 | 5258 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 249 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 249 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2018 | 312 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2016 | 432 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 347 | 0.030 |
Why?
|
| Deoxycytidine | 2 | 2012 | 1389 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2016 | 85 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 335 | 0.030 |
Why?
|
| Karyopherins | 1 | 2017 | 134 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 432 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2022 | 1104 | 0.030 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 10728 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 463 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2016 | 203 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 250 | 0.030 |
Why?
|
| Glycolysis | 1 | 2018 | 529 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 285 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2018 | 210 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 326 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 106 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 694 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 109 | 0.030 |
Why?
|
| Patient Selection | 1 | 2022 | 2029 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 796 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 923 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 2312 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1828 | 0.030 |
Why?
|
| Survivors | 1 | 2019 | 1021 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1458 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 2013 | 14 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 156 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1607 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2005 | 5246 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 649 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 4332 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 617 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 14037 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2012 | 233 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 3490 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 632 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 509 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 2033 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2017 | 12035 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 288 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 666 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2013 | 626 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2180 | 0.020 |
Why?
|
| Benzamides | 1 | 2017 | 1879 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 149 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 128 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 1293 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 612 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3058 | 0.020 |
Why?
|
| Algorithms | 1 | 2022 | 3905 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5417 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 1535 | 0.020 |
Why?
|
| Hypoxia | 1 | 2013 | 469 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3040 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2013 | 586 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 1323 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 3707 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1355 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3241 | 0.020 |
Why?
|
| Proteomics | 1 | 2017 | 1425 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2657 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 7921 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 1436 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 1381 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1715 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2004 | 703 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2013 | 750 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 5605 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2468 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 884 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 3534 | 0.020 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cystadenoma, Serous | 1 | 2005 | 31 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3392 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2005 | 170 | 0.020 |
Why?
|
| Microwaves | 1 | 2005 | 33 | 0.020 |
Why?
|
| Pancreatic Fistula | 1 | 2005 | 102 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1042 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 2005 | 127 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 651 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2017 | 3670 | 0.010 |
Why?
|
| Piperazines | 1 | 2013 | 2142 | 0.010 |
Why?
|
| Cadaver | 1 | 2005 | 202 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 2769 | 0.010 |
Why?
|
| Infant | 2 | 2015 | 14000 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2005 | 370 | 0.010 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2005 | 193 | 0.010 |
Why?
|
| Splenectomy | 1 | 2004 | 166 | 0.010 |
Why?
|
| Philadelphia Chromosome | 1 | 2007 | 852 | 0.010 |
Why?
|
| Reoperation | 1 | 2005 | 1388 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 2005 | 514 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2003 | 1990 | 0.010 |
Why?
|
| Myasthenia Gravis | 1 | 2000 | 106 | 0.010 |
Why?
|
| Thymoma | 1 | 2000 | 252 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 2068 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 2509 | 0.010 |
Why?
|
| Thymus Neoplasms | 1 | 2000 | 416 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2001 | 1174 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 7788 | 0.010 |
Why?
|
| Liver | 1 | 2001 | 3058 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 5675 | 0.010 |
Why?
|